# Windlas Biotech share price today (Windlas Biotech Ltd, NSE: WINDLAS)

> Windlas Biotech share price today: ₹879.60 at the NSE close on 3 November 2026, down 7.0% in a year. Windlas Biotech (NSE: WINDLAS) is worth ₹1,815 crore, trades at a P/E of 27.3 and has closed between ₹723.35 and ₹1,129.25 over the past 52 weeks. > Windlas Biotech Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. WINDLAS · Pharma - API & CRAMS · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/windlas-biotech-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Growing steadily, from the last 12 quarters
- Price: ₹879.60 (−7.0% in a year)
- P/E: 27.3× (higher than 66% of the last 5.2 years)
- Revenue (Jun 2026): ₹248 Cr (+18.1% on a year ago)
- Profit (Jun 2026): ₹18.0 Cr (+0.0% on a year ago)
- Operating margin: 11.0% (−2.0 points on a year ago)
- ROCE: 16%, FY26
- ROIC: 16.9%, against a 12.0% cost of capital: +4.9 points

Biggest thing to watch: the P/E is higher than 66% of its own history, so the multiple has already done part of the work. ## What is the Windlas Biotech share price today? Windlas Biotech Ltd's share price was ₹879.60 at the close on 3 November 2026. It has been rising for 13 weeks. That is 3.3% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹723 and ₹1,129, and at that close it sat 38% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 1 week running. Over the last 5.2 years the share price moved +140% while the NIFTY 500 moved +55%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 30 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Windlas Biotech this quarter? Three changes stood out: revenue up on a year earlier for 11 quarters in a row (every quarter we can compare), indian funds and insurers (DIIs) cut their stake for 3 quarters in a row and foreign funds (FIIs) raised their stake for 3 quarters in a row. 1. Revenue up on a year earlier for 11 quarters in a row (every quarter we can compare) In the June 2026 quarter revenue was ₹248 crore, +18.1% on a year earlier. Why: Revenue rose because the CDMO business brought in more work from existing customers and new product launches. That business led the quarter. From the earnings call on 11 Aug 2026. 2. Indian funds and insurers (DIIs) cut their stake for 3 quarters in a row From 11.8% to 7.2% of the company by the September 2026 quarter. 3. Foreign funds (FIIs) raised their stake for 3 quarters in a row From 0.6% to 2.1% of the company by the September 2026 quarter. ## What are Windlas Biotech's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Windlas Biotech reported revenue of ₹248 crore, up 18.1% from ₹210 crore a year earlier, and a profit of ₹18.0 crore, up 0.0% from ₹18.0 crore. ### Windlas Biotech results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹248 crore | ₹210 crore | +18.1% |
| Profit | ₹18.0 crore | ₹18.0 crore | 0.0% |
| Earnings per share | ₹8.55 | ₹8.43 | +1.4% |
| Operating margin | 11.0% | 13.0% | −2.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Windlas Biotech's management discussed these results on a call held on 11 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Windlas Biotech share price history? Windlas Biotech closed at ₹879.60 on 3 November 2026, down 7.0% from ₹945.50 a year earlier (31 October 2025) and up 183.8% over five years. Its highest weekly close since August 2021 was ₹1,144.25 on 6 December 2024. ### Windlas Biotech share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹872.70 | +0.8% |
| 1 month ago · 1 Oct 2026 | ₹1,082.40 | −18.7% |
| 6 months ago · 30 Apr 2026 | ₹851.85 | +3.3% |
| 1 year ago · 31 Oct 2025 | ₹945.50 | −7.0% |
| 3 years ago · 3 Nov 2023 | ₹364.70 | +141.2% |
| 5 years ago · 4 Nov 2021 | ₹309.90 | +183.8% |
| Earliest weekly close in our records · 20 Aug 2021 | ₹366.70 | +139.9% |
| Highest weekly close since August 2021 · 6 Dec 2024 | ₹1,144.25 | −23.1% |
| Lowest weekly close since August 2021 · 29 Jul 2022 | ₹210.80 | +317.3% |
| 52-week high (weekly close) · 11 Sep 2026 | ₹1,129.25 | −22.1% |
| 52-week low (weekly close) · 13 Mar 2026 | ₹723.35 | +21.6% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (277 weekly closes from 20 August 2021 to 3 November 2026.)

## What is the latest news on Windlas Biotech? 3 Nov 2026: Windlas Biotech closed at ₹879.60, up 0.8% on the week and down 18.7% on the month. 11 Aug 2026: Windlas Biotech held its results call for April to June 2026. Management guided: Plant 6 commercialization planned by end-July to September 2026, with a roughly two-week variance. ### Earlier

- 16 Jul 2026: ex-date for a dividend of ₹6.30 a share. - Results for April to June 2026: Revenue up 18.1% and profit up 0.0% on a year earlier. ## What dividend does Windlas Biotech pay? Windlas Biotech paid ₹6.30 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.72% at the ₹879.60 close on 3 November 2026. The last was a dividend of ₹6.30 a share, ex-date 16 July 2026. ### Windlas Biotech dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 16 Jul 2026 | ₹6.30 | Dividend |
| 21 Jul 2025 | ₹5.80 | Dividend |
| 17 Sep 2024 | ₹5.50 | Dividend |
| 5 Sep 2023 | ₹4 | Dividend |
| 9 Sep 2022 | ₹3.50 | Dividend |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 4 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Windlas Biotech Ltd paid out 20% of its profit as dividends in FY26, and it paid a dividend in 5 of its last 11 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Windlas Biotech management say on the latest results call? On the call for April to June 2026, held on 11 August 2026, Windlas Biotech's management guided: Plant 6 commercialization planned by end-July to September 2026, with a roughly two-week variance. > “The momentum has taken a hit, but I would say that this is a temporary hit for a few quarters rather than a long-term issue.”
> Komal Gupta, CEO & CFO, on the call for April to June 2026

### What management guided

- Plant 6-supported total revenue ₹1,100 crore initially, with further ₹100-150 crore possible through efficiency and debottlenecking. - Peak utilization of 60-65%, stretchable around 70% as operational capacity expands. - Initial Plant 6 depreciation around ₹30 million per quarter, +/- 10-15%; partial impact starts at commissioning and full effect in the following quarter. - Injectables capacity addition would take 6-8 months from decision through qualification and commissioning; no decision announced. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/43984/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 11 August 2026.)

## What to watch in Windlas Biotech's next results? When Windlas Biotech reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Plant 6 commissioning milestone - check validation completion, customer approvals and initial revenue and cash-flow conversion. - What to check (from the call)
- Plant 6 commissioning milestone - check validation completion, customer approvals and initial revenue and cash-flow conversion. - Trade-generics rebuild - check whether non-codeine liquids, broader SKUs and geographic expansion restore momentum. - Export pipeline - check whether registrations, plant approvals and new geographies convert into repeat revenue. - CDMO quality and API conditions - check whether product mix support offsets input volatility in the next print. ## Which stock lists is Windlas Biotech on? Windlas Biotech is on one of our India lists: Pharma stocks. [Pharma stocks Market value (₹ crore): 1877.2368451090058](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Windlas Biotech profitable? Windlas Biotech Ltd earned ₹18.0 Cr of net profit in the Jun 2026 quarter, +0.0% on the same quarter a year earlier. Full-year FY26 profit was ₹66.0 Cr. Over 10 years profit has grown 29.4% a year on average. That is 7.3% of the quarter's revenue. The same quarter a year earlier earned ₹18.0 Cr. For the full year, FY26 profit was ₹66.0 Cr (+8.2% on the year before). Why profit moved: revenue changed +18.1% on a year earlier and the margin moved −2.0 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed +3.1% and revenue +18.4%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Windlas Biotech make, and is it growing? Windlas Biotech Ltd reported ₹248 Cr of revenue in the Jun 2026 quarter, +18.1% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 12.7% a year on average. The last full year, FY26, came in at ₹904 Cr. The last four reported quarters add to ₹941 Cr. FY26 revenue was ₹904 Cr, +18.9% on the year before. Recent pace: the last four quarters grew +18.4% on average, against 12.7% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +18.4%, against +19.3% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +3.1%, against +6.6% a year (rolling over). ## How much of every ₹100 of sales does Windlas Biotech keep? Windlas Biotech Ltd's operating margin was 11.0% in the Jun 2026 quarter, 2.0 percentage points lower than the same quarter a year ago. Across 11 years it has been between 7.0% and 15.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −1.9 percentage points on the year while gross margin changed +0.2 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Windlas Biotech's profit turning into cash? Over the last 3 years, 152% of Windlas Biotech Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹105 Cr of operating cash against ₹66.0 Cr of profit. After ₹76.0 Cr of spending on assets, ₹29.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 152% of profit came in as cash: the cash cycle got 94 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner. What to look at next: the bigger use of cash is spending on new assets, at 3.1× depreciation over three years. The next section checks what that spending is building. ## Where does Windlas Biotech's cash go? Windlas Biotech Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was −24 days in FY26, down from 70 days in FY21. It spent ₹221 Cr on assets over the last 3 years. Customers take 92 days to pay, and stock sits for 40 days on average. At FY26 sales of ₹904 Cr, each day of that cycle ties up about ₹2.5 Cr, so roughly −₹59.0 Cr is tied up in the business at any time. FY26: customers took 92 days to pay and stock sat for 40 days, about 1.3 months of sales sitting as stock, for a full cycle of −24 days, shorter than FY21's 70. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 40 days. Customers pay about 92 days after that. Suppliers are paid at 156 days. Together that makes the −24-day cycle. Spending on assets: ₹221 Cr over the last 3 years, against ₹72.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹60.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Windlas Biotech's P/E ratio, and how does it compare with its own history? Windlas Biotech Ltd's P/E is 27.3×, in the middle of its own history: higher than 66% of past readings. Its usual P/E (the middle reading) is 24.8×, over 5.2 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹31.68. Why the multiple is where it is: over the past year earnings per share moved +8.8% while the price moved −7.0%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved +23.2% a year; about +25.6% a year came from earnings growth and about −2.4 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Windlas Biotech business getting better or worse? Windlas Biotech Ltd's business is growing steadily. Revenue, profit and EPS growth have stayed positive throughout, and ROCE is steady at 16.8%. This is based on 12 quarters of 4 measures. Why it matters: steady growth with healthy returns is how a business compounds over time. ## How much does Windlas Biotech earn on its capital? Windlas Biotech Ltd earned a ROCE of 16% in FY26. That is up from a low of 10% in FY17. Its return on capital used (ROIC) is 4.9 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 7.3% net margin and 1.00× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 7.3% net margin × 1.00× asset turnover × 1.56× leverage (assets divided by equity) ≈ 11.4% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 16.9% − 12.0% = +4.9 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error. ## Does Windlas Biotech have too much debt? Windlas Biotech Ltd has total debt of ₹35.0 Cr against shareholder equity of ₹581 Cr as of Jun 2026, so its debt is 0.06× its equity, which is very little. Year by year, that ratio went from 0.02 in FY22 to 0.06 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Windlas Biotech shareholding pattern? Domestic institutions cut their stake in Windlas Biotech Ltd by 3.0 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 7.2% of the company. Promoters moved +0.8 points over the same period, to 63.3%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: −3.0 points over 8 quarters, to 7.2%; Promoters: +0.8 points over 8 quarters, to 63.3%; Foreign institutions: +0.5 points over 8 quarters, to 2.1%. Why the owners changed: domestic institutions drove it (−3.0 points), with the other side taken by promoters (+0.8 points). They reduced their stake. ## How far is Windlas Biotech from balance-sheet trouble? For Windlas Biotech Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Windlas Biotech rank in its industry? 47.6 out of 100, rank 14 of 24 in Pharma - API & CRAMS, with 81% of the evidence available. Windlas Biotech Ltd scores 47.6 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 14. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 14.5 + 13.6 + 9.1 + 10.4 = 47.6. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Windlas Biotech compared with? Windlas Biotech ranks 14 of 24 Pharma - API & CRAMS companies on the 4-Factor Sector Score, with 47.6 out of 100. 1. [Neuland Laboratories Ltd](https://www.sectoralpha.in/stocks/neuland-laboratories-ltd) NEULANDLAB · leader · Most evidence points up · 96% evidence 76.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.3/35 · Revenue 78.3% · Profit 100% · Operating margin change 23 points · 88% evidence Capital efficiency 22.9/25 · ROCE 26.5% · Operating margin 35% · 100% evidence Valuation 14.1/20 · P/E 50.8× · PEG 1.04 · 100% evidence Relative strength 6.7/20 · Lead over its industry -7.8% · Lead over NIFTY 500 20.3% · 1 year 19.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 32.3 + 22.9 + 14.1 + 6.7 = 76 · What this means: Earnings are strong; relative strength in its sector is -7.8% and the one-year return is 19.6%. 2. [Acutaas Chemicals Ltd](https://www.sectoralpha.in/stocks/acutaas-chemicals-ltd) ACUTAAS · turning · Most evidence points up · 67% evidence 73.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.3/35 · Revenue 45.4% · Profit 95.5% · Operating margin change 9 points · 95% evidence Capital efficiency 20.3/25 · ROCE 31.6% · Operating margin 40% · 76% evidence Valuation 10.2/20 · P/E 74.6× · PEG n/a · 50% evidence Relative strength 12.1/20 · Lead over its industry n/a · Lead over NIFTY 500 59.6% · 1 year 131.7% · 25% evidence · 2 of 9 weeks ahead Exact sum: 31.3 + 20.3 + 10.2 + 12.1 = 73.9 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Laurus Labs Ltd](https://www.sectoralpha.in/stocks/laurus-labs-ltd) LAURUSLABS · leader · Most evidence points up · 93% evidence 71.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.9/35 · Revenue 23% · Profit 95.3% · Operating margin change 10 points · 100% evidence Capital efficiency 17.3/25 · ROCE 17.8% · Operating margin 34% · 100% evidence Valuation 5.8/20 · P/E 97× · PEG 2.98 · 65% evidence Relative strength 17.0/20 · Lead over its industry 42.3% · Lead over NIFTY 500 82.8% · 1 year 152.2% · 100% evidence · 12 of 12 weeks ahead Exact sum: 30.9 + 17.3 + 5.8 + 17 = 71 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. [Gland Pharma Ltd](https://www.sectoralpha.in/stocks/gland-pharma-ltd) GLAND · leader · Most evidence points up · 96% evidence 69.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.0/35 · Revenue 17.6% · Profit 46.4% · Operating margin change 3 points · 88% evidence Capital efficiency 16.0/25 · ROCE 15.1% · Operating margin 27% · 100% evidence Valuation 12.1/20 · P/E 44.6× · PEG 1.45 · 100% evidence Relative strength 16.8/20 · Lead over its industry 15.1% · Lead over NIFTY 500 49.3% · 1 year 60.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 25 + 16 + 12.1 + 16.8 = 69.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [IOL Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/iol-chemicals-pharmaceuticals-ltd) IOLCP · leader · Most evidence points up · 100% evidence 69.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 26.7% · Profit 75% · Operating margin change 4 points · 100% evidence Capital efficiency 12.8/25 · ROCE 11.3% · Operating margin 14% · 100% evidence Valuation 13.9/20 · P/E 24.6× · PEG 0.66 · 100% evidence Relative strength 13.9/20 · Lead over its industry 21.6% · Lead over NIFTY 500 53.8% · 1 year 92.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.1 + 12.8 + 13.9 + 13.9 = 69.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Shilpa Medicare Ltd](https://www.sectoralpha.in/stocks/shilpa-medicare-ltd) SHILPAMED · leader · Most evidence points up · 89% evidence 67.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.4/35 · Revenue 28% · Profit 100% · Operating margin change 1 points · 88% evidence Capital efficiency 10.8/25 · ROCE 10.9% · Operating margin 29% · 100% evidence Valuation 9.9/20 · P/E 65.7× · PEG 1.73 · 65% evidence Relative strength 19.9/20 · Lead over its industry 47.2% · Lead over NIFTY 500 84.2% · 1 year 170.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 26.4 + 10.8 + 9.9 + 19.9 = 67 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Morepen Laboratories Ltd](https://www.sectoralpha.in/stocks/morepen-laboratories-ltd) MOREPENLAB · leader · Evidence leans up · 85% evidence 62.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.8/35 · Revenue 30.1% · Profit 90.9% · Operating margin change 9 points · 100% evidence Capital efficiency 9.3/25 · ROCE 8.1% · Operating margin 16% · 100% evidence Valuation 8.5/20 · P/E 32.9× · PEG 2.14 · 100% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 94.5% · 1 year 139% · 25% evidence · 12 of 12 weeks ahead Exact sum: 31.8 + 9.3 + 8.5 + 12.5 = 62.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Divis Laboratories Ltd](https://www.sectoralpha.in/stocks/divis-laboratories-ltd) DIVISLAB · leader · Evidence leans up · 96% evidence 61.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.7/35 · Revenue 16.4% · Profit 26.8% · Operating margin change 11 points · 88% evidence Capital efficiency 18.6/25 · ROCE 22% · Operating margin 41% · 100% evidence Valuation 2.6/20 · P/E 87.1× · PEG 3.45 · 100% evidence Relative strength 15.5/20 · Lead over its industry 9.2% · Lead over NIFTY 500 43.1% · 1 year 45.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.7 + 18.6 + 2.6 + 15.5 = 61.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 9. [Granules India Ltd](https://www.sectoralpha.in/stocks/granules-india-ltd) GRANULES · turning · Evidence leans up · 96% evidence 57.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.3/35 · Revenue 24.8% · Profit 38.1% · Operating margin change 3 points · 88% evidence Capital efficiency 16.2/25 · ROCE 15.5% · Operating margin 23% · 100% evidence Valuation 10.2/20 · P/E 35.2× · PEG 1.29 · 100% evidence Relative strength 6.7/20 · Lead over its industry -5.2% · Lead over NIFTY 500 24.2% · 1 year 48.5% · 100% evidence · 7 of 12 weeks ahead Exact sum: 24.3 + 16.2 + 10.2 + 6.7 = 57.4 · What this means: Earnings are strong; relative strength in its sector is -5.2% and the one-year return is 48.5%. 10. [Sai Life Sciences Ltd](https://www.sectoralpha.in/stocks/sai-life-sciences-ltd) SAILIFE · leader · Evidence leans up · 89% evidence 57.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.7/35 · Revenue 17.6% · Profit 48% · Operating margin change 3 points · 88% evidence Capital efficiency 17.0/25 · ROCE 19.6% · Operating margin 27% · 100% evidence Valuation 4.8/20 · P/E 90× · PEG 3.63 · 65% evidence Relative strength 13.8/20 · Lead over its industry 9.9% · Lead over NIFTY 500 42.9% · 1 year 69.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.7 + 17 + 4.8 + 13.8 = 57.3 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 11. [SMS Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/sms-pharmaceuticals-ltd) SMSPHARMA · breaking out · Evidence leans up · 96% evidence 55.8 out of 100 Growth Capital Valuation Relative
12. [Blue Jet Healthcare Ltd](https://www.sectoralpha.in/stocks/blue-jet-healthcare-ltd) BLUEJET · quiet · Evidence leans up · 81% evidence 52.7 out of 100 Growth Capital Valuation Relative
13. [Solara Active Pharma Sciences Ltd](https://www.sectoralpha.in/stocks/solara-active-pharma-sciences-ltd) SOLARA · breaking out · Evidence leans down · 74% evidence 49.5 out of 100 Growth Capital Valuation Relative
14. Windlas Biotech Ltd this page WINDLAS · leader · Evidence leans down · 81% evidence 47.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.5/35 · Revenue 18.4% · Profit 3.1% · Operating margin change -2 points · 88% evidence Capital efficiency 13.6/25 · ROCE 15.9% · Operating margin 11% · 100% evidence Valuation 9.1/20 · P/E 27.2× · PEG 3.02 · 100% evidence Relative strength 10.4/20 · Lead over its industry n/a · Lead over NIFTY 500 7.3% · 1 year -7.3% · 25% evidence · 12 of 12 weeks ahead Exact sum: 14.5 + 13.6 + 9.1 + 10.4 = 47.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 15. [Anthem Biosciences Ltd](https://www.sectoralpha.in/stocks/anthem-biosciences-ltd) ANTHEM · leader · Evidence leans down · 89% evidence 46.7 out of 100 Growth Capital Valuation Relative
16. [Piramal Pharma Ltd](https://www.sectoralpha.in/stocks/piramal-pharma-ltd) PPLPHARMA · leader · Evidence leans down · 71% evidence 44.6 out of 100 Growth Capital Valuation Relative
17. [Supriya Lifescience Ltd](https://www.sectoralpha.in/stocks/supriya-lifescience-ltd) SUPRIYA · breaking out · Evidence leans down · 96% evidence 43.7 out of 100 Growth Capital Valuation Relative
18. [Concord Biotech Ltd](https://www.sectoralpha.in/stocks/concord-biotech-ltd) CONCORDBIO · quiet · Evidence leans down · 85% evidence 40.8 out of 100 Growth Capital Valuation Relative
19. [Jubilant Pharmova Ltd](https://www.sectoralpha.in/stocks/jubilant-pharmova-ltd) JUBLPHARMA · turning · Most evidence points down · 86% evidence 30.3 out of 100 Growth Capital Valuation Relative
20. [Hikal Ltd](https://www.sectoralpha.in/stocks/hikal-ltd) HIKAL · turning · Most evidence points down · 78% evidence 29.7 out of 100 Growth Capital Valuation Relative
21. [OneSource Specialty Pharma Ltd](https://www.sectoralpha.in/stocks/onesource-specialty-pharma-ltd) ONESOURCE · turning · Most evidence points down · 83% evidence 29.2 out of 100 Growth Capital Valuation Relative
22. [Syngene International Ltd](https://www.sectoralpha.in/stocks/syngene-international-ltd) SYNGENE · turning · Most evidence points down · 100% evidence 27.8 out of 100 Growth Capital Valuation Relative
23. [Cohance Lifesciences Ltd](https://www.sectoralpha.in/stocks/cohance-lifesciences-ltd) COHANCE · breaking out · Most evidence points down · 78% evidence 27.1 out of 100 Growth Capital Valuation Relative
24. [Dishman Carbogen Amcis Ltd](https://www.sectoralpha.in/stocks/dishman-carbogen-amcis-ltd) DCAL · basing · Most evidence points down · 64% evidence 27.0 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - API & CRAMS](https://www.sectoralpha.in/sectors/pharma-api-crams), all 24 compared on one page. ## Which companies are close to Windlas Biotech in size? Windlas Biotech is the 24th largest of 24 Pharma - API & CRAMS companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Morepen Laboratories, IOL Chemicals & Pharmaceuticals, SMS Pharmaceuticals, Solara Active Pharma Sciences, Hikal and Dishman Carbogen Amcis. It is the smallest. ### Pharma - API & CRAMS companies close in size

1. [Morepen Laboratories Ltd](https://www.sectoralpha.in/stocks/morepen-laboratories-ltd) ₹6,211 crore
2. [IOL Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/iol-chemicals-pharmaceuticals-ltd) ₹5,215 crore
3. [SMS Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/sms-pharmaceuticals-ltd) ₹4,789 crore
4. [Solara Active Pharma Sciences Ltd](https://www.sectoralpha.in/stocks/solara-active-pharma-sciences-ltd) ₹3,070 crore
5. [Hikal Ltd](https://www.sectoralpha.in/stocks/hikal-ltd) ₹2,609 crore
6. [Dishman Carbogen Amcis Ltd](https://www.sectoralpha.in/stocks/dishman-carbogen-amcis-ltd) ₹2,274 crore
7. Windlas Biotech Ltd ₹1,808 crore

[All 24 Pharma - API & CRAMS companies, largest first](https://www.sectoralpha.in/sectors/pharma-api-crams#all-companies)

### Companies close in size in other industries

1. [Kross Ltd](https://www.sectoralpha.in/stocks/kross-ltd) ₹1,809 crore · Auto Ancillaries - Transmission
2. [Syncom Formulations (India) Ltd](https://www.sectoralpha.in/stocks/syncom-formulations-indialtd) ₹1,809 crore · Pharma - Others
3. Windlas Biotech Ltd ₹1,808 crore
4. [Schneider Electric President Systems Ltd](https://www.sectoralpha.in/stocks/schneider-electric-president-systems-ltd) ₹1,803 crore
5. [Sika Interplant Systems Ltd](https://www.sectoralpha.in/stocks/sika-interplant-systems-ltd) ₹1,799 crore · Aerospace & Defence - Equipments

## What else do people ask about Windlas Biotech? ### What is Windlas Biotech's share price today? Windlas Biotech Ltd's share price is ₹879.60, −7.0% over the past year. The whole company is worth ₹1,815 Cr on the market. In the last 52 weeks it traded between ₹723 to ₹1,129; today it is 38% of the way up from the low, 3.3% below its 200-day average (as of 3 November 2026). ### What were Windlas Biotech's latest quarterly results? Windlas Biotech Ltd reported revenue of ₹248 Cr and net profit of ₹18.0 Cr for the Jun 2026 quarter. Revenue rose 18.1% and profit rose 0.0% compared with a year earlier. Earnings per share were ₹8.55. The operating margin was 11.0%, 2.0 percentage points lower than a year earlier (as of 3 November 2026). ### What is Windlas Biotech's market cap? Windlas Biotech Ltd's market capitalisation is ₹1,815 Cr at a share price of ₹879.60. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Windlas Biotech performing? Windlas Biotech Ltd's share price has been rising for 13 weeks. In its latest quarter, revenue rose 18.1% and profit rose 0.0% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 1 week running (as of 3 November 2026). ### Will Windlas Biotech's share price go up? This page does not forecast Windlas Biotech Ltd's share price. What it shows instead: the share price is ₹879.60, and it has been rising for 13 weeks. Its P/E of 27.3× is higher than 66% of its own last 5 years (as of 3 November 2026). ### Who owns Windlas Biotech? Promoters own 63.3% of Windlas Biotech Ltd, foreign institutions 2.1%, domestic institutions 7.2% and the public 27.4% (latest quarter). The biggest change over the last two years: Domestic institutions cut their stake by 3.0 percentage points over 8 quarters (as of 3 November 2026). ### Where is Windlas Biotech in its business cycle? Windlas Biotech Ltd's FY26 operating margin was 12.0%, against a 11-year range of 7.0% to 15.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 11.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Windlas Biotech story? Biggest thing to watch: the P/E is higher than 66% of its own history, so the multiple has already done part of the work. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Windlas Biotech a stock worth studying right now? What the numbers show: Windlas Biotech Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Windlas Biotech share price forecast for 2026? What management itself guided: Plant 6 commercialization planned by end-July to September 2026, with a roughly two-week variance. ## Lists

- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.